“ambit-biosciences” Archives

Entry Author Date Location
Ambit Raises $30M Venture Round, After Pulling Plug on IPO 06/10/11 San Diego
Ambit Biosciences Receives $30,000,000 Series D Funding Round 06/10/11 San Diego
Orexigen Halts U.S. Work on Weight Loss Drug, Illumina Cuts Price for Sequencing Patient Genomes, Ambit Pulls IPO, & More San Diego Life Sciences News 06/09/11 San Diego
Ambit Withdraws IPO 06/08/11 San Diego
IPO Pipeline Pumps Up the Volume in First Quarter 05/23/11 National
Ambit Files for IPO, Arena Pharmaceuticals Says Weight-Loss Drug on Track, ESRI Launches Medical Place History Map App, & More San Diego Life Sciences News 11/12/10 San Diego
Ambit Biosciences Seeks $86M IPO as Market Warms Up 11/08/10 San Diego
Amylin Regroups From FDA Smackdown, CalciMedica Plans Trial of New Anti-Immune Drug, FDA Gives CareFusion Recall Highest Priority, & More San Diego Life Science News 10/21/10 San Diego
Ambit Bio Raises $15M 10/19/10 San Diego
Ambit Biosciences Lands $14,999,327 New Funding 10/19/10 San Diego
Genomics in San Diego: From the Human Genome to a New Biotechnology Focus 08/13/10 San Diego
Femta Pharmaceuticals Snags $2.2M for Potent Antibody Drugs 07/13/10 San Diego
For General Corporate Purposes: A Roundup of San Diego Startups Raising Capital 04/16/10 San Diego
San Diego’s aFraxis Studies Drug Candidates to Treat Fragile X Syndrome 02/03/10 San Diego
Ambit Signs Big Deal With Astellas, Xenomics Alleges Fraud at Sequenom, Arena Seeks FDA Approval for Weight-Loss Drug & More San Diego Life Sciences News 12/24/09 San Diego
Ambit, Buoyed by Astellas Deal, Attempting Rare Switch from Platform to Drug Developer 12/23/09 San Diego
Ambit Nabs Partnership With Astellas, $40M Upfront Cash, To Develop Leukemia Drug 12/18/09 San Diego
Ambit Biosciences, In Third Incarnation, Gears Up for Pivotal Study of Leukemia Drug 09/10/09 San Diego
Startups Just Want to Have Funds: A Roundup of Recent San Diego Deals 07/24/09 San Diego
Page 2 of 2 « previous page